Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats.

Toyokazu Uwatoku, Hiroaki Shimokawa, Kotaro Abe, Yasuharu Matsumoto, Tsuyoshi Hattori, Keiji Oi, Takehisa Matsuda, Kazunori Kataoka, Akira Takeshita

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Restenosis after percutaneous coronary intervention continues to be a serious problem in clinical cardiology. Recent advances in nanoparticle technology have enabled us to deliver an antiproliferative drug selectively to the balloon-injured artery for a longer time. NK911, which is a core-shell nanoparticle of polyethyleneglycol-based block copolymer encapsulating doxorubicin, accumulates in vascular lesions with increased permeability. We first confirmed that balloon injury caused a marked and sustained increase in vascular permeability (as evaluated by Evans blue staining) for a week in the rat carotid artery. We then observed that intravenous administration of just 3 times of NK911, but not doxorubicin alone, significantly inhibited the neointimal formation of the rat carotid artery at 4 weeks after the injury in both a single- and double-injury model. Immunostaining demonstrated that the effect of NK911 was due to inhibition of vascular smooth muscle proliferation but not to enhancement of apoptosis or inhibition of inflammatory cell recruitment. Measurement of vascular concentrations of doxorubicin confirmed the effective delivery of the agent to the balloon-injured artery by NK911 in both a single- and double-injury model. RNA protection assay demonstrated that NK911 inhibited expression of several cytokines but not that of apoptosis-related molecules. NK911 was well tolerated without any adverse systemic effects. These results suggest that nanoparticle technology to target vascular lesions with increased permeability is a promising and safe approach for the prevention of restenosis after balloon injury. The full text of this article is available at http://www.circresaha.org.

Original languageEnglish
JournalCirculation research
Volume92
Issue number7
Publication statusPublished - Jan 1 2003

Fingerprint

Nanoparticles
Technology
Wounds and Injuries
Doxorubicin
Blood Vessels
Carotid Arteries
Permeability
Arteries
Apoptosis
Evans Blue
Capillary Permeability
Percutaneous Coronary Intervention
Cardiology
Vascular Smooth Muscle
Intravenous Administration
NK911
RNA
Staining and Labeling
Cytokines
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Uwatoku, T., Shimokawa, H., Abe, K., Matsumoto, Y., Hattori, T., Oi, K., ... Takeshita, A. (2003). Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circulation research, 92(7).

Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. / Uwatoku, Toyokazu; Shimokawa, Hiroaki; Abe, Kotaro; Matsumoto, Yasuharu; Hattori, Tsuyoshi; Oi, Keiji; Matsuda, Takehisa; Kataoka, Kazunori; Takeshita, Akira.

In: Circulation research, Vol. 92, No. 7, 01.01.2003.

Research output: Contribution to journalArticle

Uwatoku, T, Shimokawa, H, Abe, K, Matsumoto, Y, Hattori, T, Oi, K, Matsuda, T, Kataoka, K & Takeshita, A 2003, 'Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats.', Circulation research, vol. 92, no. 7.
Uwatoku, Toyokazu ; Shimokawa, Hiroaki ; Abe, Kotaro ; Matsumoto, Yasuharu ; Hattori, Tsuyoshi ; Oi, Keiji ; Matsuda, Takehisa ; Kataoka, Kazunori ; Takeshita, Akira. / Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. In: Circulation research. 2003 ; Vol. 92, No. 7.
@article{c74e26819baf47c1994bfbb5022323fe,
title = "Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats.",
abstract = "Restenosis after percutaneous coronary intervention continues to be a serious problem in clinical cardiology. Recent advances in nanoparticle technology have enabled us to deliver an antiproliferative drug selectively to the balloon-injured artery for a longer time. NK911, which is a core-shell nanoparticle of polyethyleneglycol-based block copolymer encapsulating doxorubicin, accumulates in vascular lesions with increased permeability. We first confirmed that balloon injury caused a marked and sustained increase in vascular permeability (as evaluated by Evans blue staining) for a week in the rat carotid artery. We then observed that intravenous administration of just 3 times of NK911, but not doxorubicin alone, significantly inhibited the neointimal formation of the rat carotid artery at 4 weeks after the injury in both a single- and double-injury model. Immunostaining demonstrated that the effect of NK911 was due to inhibition of vascular smooth muscle proliferation but not to enhancement of apoptosis or inhibition of inflammatory cell recruitment. Measurement of vascular concentrations of doxorubicin confirmed the effective delivery of the agent to the balloon-injured artery by NK911 in both a single- and double-injury model. RNA protection assay demonstrated that NK911 inhibited expression of several cytokines but not that of apoptosis-related molecules. NK911 was well tolerated without any adverse systemic effects. These results suggest that nanoparticle technology to target vascular lesions with increased permeability is a promising and safe approach for the prevention of restenosis after balloon injury. The full text of this article is available at http://www.circresaha.org.",
author = "Toyokazu Uwatoku and Hiroaki Shimokawa and Kotaro Abe and Yasuharu Matsumoto and Tsuyoshi Hattori and Keiji Oi and Takehisa Matsuda and Kazunori Kataoka and Akira Takeshita",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "92",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats.

AU - Uwatoku, Toyokazu

AU - Shimokawa, Hiroaki

AU - Abe, Kotaro

AU - Matsumoto, Yasuharu

AU - Hattori, Tsuyoshi

AU - Oi, Keiji

AU - Matsuda, Takehisa

AU - Kataoka, Kazunori

AU - Takeshita, Akira

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Restenosis after percutaneous coronary intervention continues to be a serious problem in clinical cardiology. Recent advances in nanoparticle technology have enabled us to deliver an antiproliferative drug selectively to the balloon-injured artery for a longer time. NK911, which is a core-shell nanoparticle of polyethyleneglycol-based block copolymer encapsulating doxorubicin, accumulates in vascular lesions with increased permeability. We first confirmed that balloon injury caused a marked and sustained increase in vascular permeability (as evaluated by Evans blue staining) for a week in the rat carotid artery. We then observed that intravenous administration of just 3 times of NK911, but not doxorubicin alone, significantly inhibited the neointimal formation of the rat carotid artery at 4 weeks after the injury in both a single- and double-injury model. Immunostaining demonstrated that the effect of NK911 was due to inhibition of vascular smooth muscle proliferation but not to enhancement of apoptosis or inhibition of inflammatory cell recruitment. Measurement of vascular concentrations of doxorubicin confirmed the effective delivery of the agent to the balloon-injured artery by NK911 in both a single- and double-injury model. RNA protection assay demonstrated that NK911 inhibited expression of several cytokines but not that of apoptosis-related molecules. NK911 was well tolerated without any adverse systemic effects. These results suggest that nanoparticle technology to target vascular lesions with increased permeability is a promising and safe approach for the prevention of restenosis after balloon injury. The full text of this article is available at http://www.circresaha.org.

AB - Restenosis after percutaneous coronary intervention continues to be a serious problem in clinical cardiology. Recent advances in nanoparticle technology have enabled us to deliver an antiproliferative drug selectively to the balloon-injured artery for a longer time. NK911, which is a core-shell nanoparticle of polyethyleneglycol-based block copolymer encapsulating doxorubicin, accumulates in vascular lesions with increased permeability. We first confirmed that balloon injury caused a marked and sustained increase in vascular permeability (as evaluated by Evans blue staining) for a week in the rat carotid artery. We then observed that intravenous administration of just 3 times of NK911, but not doxorubicin alone, significantly inhibited the neointimal formation of the rat carotid artery at 4 weeks after the injury in both a single- and double-injury model. Immunostaining demonstrated that the effect of NK911 was due to inhibition of vascular smooth muscle proliferation but not to enhancement of apoptosis or inhibition of inflammatory cell recruitment. Measurement of vascular concentrations of doxorubicin confirmed the effective delivery of the agent to the balloon-injured artery by NK911 in both a single- and double-injury model. RNA protection assay demonstrated that NK911 inhibited expression of several cytokines but not that of apoptosis-related molecules. NK911 was well tolerated without any adverse systemic effects. These results suggest that nanoparticle technology to target vascular lesions with increased permeability is a promising and safe approach for the prevention of restenosis after balloon injury. The full text of this article is available at http://www.circresaha.org.

UR - http://www.scopus.com/inward/record.url?scp=2342553444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342553444&partnerID=8YFLogxK

M3 - Article

C2 - 12663484

AN - SCOPUS:2342553444

VL - 92

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 7

ER -